1
Participants
Start Date
September 30, 2010
Primary Completion Date
May 31, 2011
Study Completion Date
May 31, 2012
Lenalidomide, Liposomal Doxorubicin, Bevacizumab
"At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.~Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease."
Revlimid, Doxil, Avastin
At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
University of New Mexico Cancer Center, Albuquerque
Collaborators (1)
Celgene Corporation
INDUSTRY
New Mexico Cancer Research Alliance
OTHER